Related references
Note: Only part of the references are listed.Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates
Michael Broeker
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
Sabrina Genssler et al.
ONCOIMMUNOLOGY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Human Glioblastoma- associated Microglia/Monocytes Express a Distinct RNA Profile Compared to Human Control and Murine Samples
Frank Szulzewsky et al.
GLIA (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Aberrant Notch signaling in glioblastoma stem cells contributes to tumor recurrence and invasion
Jian-Bo Yu et al.
MOLECULAR MEDICINE REPORTS (2016)
Distinct Transcriptional Programs Control Cross-Priming in Classical and Monocyte-Derived Dendritic Cells
Carlos G. Briseno et al.
CELL REPORTS (2016)
Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
Michael Zhang et al.
PLOS ONE (2016)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Duane A. Mitchell et al.
NATURE (2015)
Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma
Benjamin M. Zussman et al.
NEUROSURGERY (2015)
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Stephan Herbertz et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Pitfalls in le neuroimaging of glioblastoma in le era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response
Raymond Y. Huang et al.
FRONTIERS IN NEUROLOGY (2015)
Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
Nabil Ahmed et al.
Journal for ImmunoTherapy of Cancer (2015)
Principles of T2*- Weighted Dynamic Susceptibility Contrast MRI Technique in Brain Tumor Imaging
Mark S. Shiroishi et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2015)
Peptide vaccines for the treatment of glioblastoma
Adam M. Swartz et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance
Jinquan Cai et al.
PLOS ONE (2015)
CD103+ Dendritic Cells Producing Interleukin-12 in Anticancer Immunosurveillance
Laurence Zitvogel et al.
CANCER CELL (2014)
Dendritic Cell-Based Vaccine for the Treatment of Malignant Glioma: A Systematic Review
Xuan Wang et al.
CANCER INVESTIGATION (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
Peter J. Murray et al.
IMMUNITY (2014)
In vivo discovery of immunotherapy targets in the tumour microenvironment
Penghui Zhou et al.
NATURE (2014)
T11TS inhibits glioma angiogenesis by modulation of MMPs, TIMPs, with related integrin αv and TGF-β1 expressions
Manoj Kumar Singh et al.
TUMOR BIOLOGY (2014)
Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy
Sadhak Sengupta et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Immunovirotherapy for the treatment of glioblastoma
Tooba A. Cheema et al.
ONCOIMMUNOLOGY (2014)
Exomics and immunogenics Bridging mutational load and immune checkpoints efficacy
Stephane Champiat et al.
ONCOIMMUNOLOGY (2014)
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Surasak Phuphanich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion
Starlee Lively et al.
JOURNAL OF NEUROINFLAMMATION (2013)
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells
Klaus Mantwill et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group
Michael A. Vogelbaum et al.
NEUROSURGERY (2012)
Viral Vector-Based Therapeutic Cancer Vaccines
Cecilia Larocca et al.
CANCER JOURNAL (2011)
Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma
Nadia A. Atai et al.
IMMUNOLOGY (2011)
Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity
Brian M. Enloe et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Targeted therapy for high-grade glioma with the TGF-beta 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
U. Bogdahn et al.
NEURO-ONCOLOGY (2011)
Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions
Tony Avril et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity
Y. Piao et al.
CANCER GENE THERAPY (2009)
NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties
Roberta Castriconi et al.
JOURNAL OF IMMUNOLOGY (2009)
Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma
Robert Owen Dillman et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
Joannes F. M. Jacobs et al.
NEURO-ONCOLOGY (2009)
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology
Alba A. Brandes et al.
NEURO-ONCOLOGY (2008)
A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors
Matthew G. Fury et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment
D. Hoffmann et al.
CANCER GENE THERAPY (2007)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
PE Fecci et al.
CANCER RESEARCH (2006)
Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy
P Weybright et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2005)
Microglia function in brain tumors
JJ Watters et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion
KM Dhodapkar et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcγRI and the epidermal growth factor receptor
PK Wallace et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
Share Paper
